Case Study. Workshop group art therapy with women in the Spanish- Moroccan CEPI

Se presenta un estudio de caso de una mujer que formó parte en el Taller El Encuentro de Crear en el Centro Hispano Marroquí, reflexionamos sobre su recorrido en el taller y las posibles aportaciones que pudo suponer en su vida.We present a case study of a woman who took part in the workshop The Create Meeting in Moroccan Hispanic Center, is a journey and reflection on the process in the workshop

El lugar de la acción en los talleres de arteterapia

Las relaciones que se pueden llegar a establecer entre performance y arteterapia han despertado la presente investigación con el objetivo de reflexionar sobre el papel que el arte de acción puede tener en los espacios arteterapéuticos. El arte de acción (performance) en relación al arteterapia se presenta como vía que, partiendo de lo corporal, puede ayudar a las personas a dar sentido y generar significados en su recorrido arteterapeútico. El arte de acción y las obras de sus artistas nos permiten indagar sobre las peculiaridades de este ámbito artístico, se enfatiza en los tres pilares que constituyen la performance: presencia, espacio y tiempo. Un recorrido por los procesos de creación en arteterapia nos ayuda a reflexionar sobre sus posibles formas y aportaciones a la persona. Los tres análisis de casos de talleres diferentes, que tienen en común la creación espontánea articulada por la acción, nos permiten indagar sobre las posibilidades que puede ofrecer la creación performativa en talleres arteterapeúticos. [ABSTRACT] The relationships can help establish between performance and art therapy have sparked this investigation in order to reflect on the role that art can take action in Artherapy spaces. The action art (performance art) in relation to Artherapy is presented as a way that, starting from the body, can help people to make sense and create meaning in their. Artherapy process. Action art and works of its artists allow us to investigate the peculiarities of this field of art, emphasis on the three pillars of performance: presence, space and time. A journey through the creative processes in Artherapy helps us to reflect on possible ways and the individual contributions. The three case studies of different workshops, which have in common the spontaneous creation articulated by the action, allow us to investigate the potential role of performative actions in Artherapy workshops

Estudio de caso. Taller de arteterapia con grupo de mujeres en el CEPI Hispano-Marroquí

Se presenta un estudio de caso de una mujer que formó parte en el Taller El Encuentro de Crear en el Centro Hispano Marroquí, reflexionamos sobre su recorrido en el taller y las posibles aportaciones que pudo suponer en su vida

BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics

Background: Cutaneous melanoma shows high variability regarding clinicopathological presentation, evolution and prognosis. Methods: Next generation sequencing was performed to analyze hotspot mutations in different areas of primary melanomas (MMp) and their paired metastases. Clinicopathological features were evaluated depending on the degree of variation of the BRAFV600E mutant allele frequency (MAF) in MMp. Results: In our cohort of 14 superficial spreading, 10 nodular melanomas and 52 metastases, 17/24 (71%) melanomas had a BRAFV600E mutation and 5/24 (21%) had a NRASQ61 mutation. We observed a high variation of BRAFV600E MAF (H-BRAFV600E) in 7/17 (41%) MMp. The H-BRAFV600E MMp were all located on the trunk, had lower Breslow and mitotic indexes and predominantly, a first nodal metastasis. Regions with spindled tumor cells (Spin) and high lymphocytic infiltrate (HInf) were more frequent in the H-BRAFV600E patients (4/7; 57%), whereas regions with epithelial tumor cells (Epit) and low lymphocytic infiltrate (LInf) were predominant (6/10; 60%) and exclusive in the low BRAFV600E MAF variation tumors (L-BRAFV600E). The H-BRAFV600E/Spin/HInf MMp patients had better prognostic features and nodal first metastasis. Conclusions: The H-BRAFV600E MMp were located on the trunk, had better prognostic characteristics, such as lower Breslow and mitotic indexes as well as high lymphocytic infiltrate.This work was supported by grants from ISCIII and FEDER (“una manera de hacerEuropa”) PI15/00711 to RMM and PI18/00573 to RMM & AM. CIBERONC (CB16/12/00231) to XMG.Postdoctoral AECC (POSTD004MACI - POSTD16) to AM. Predoctoral UdL to PS and predoctoralAECC fellowship to IR. The work was also supported by the Xarxa de Bancs de Tumors de Catalunyasponsored by “Pla Director d’Oncologia de Catalunya (XBTC)”and IRBLleida Biobank (B.0000682)and PLATAFORMA BIOBANCOS (PT17/0015/0027; PT20/00021

Implementación de la metodología aprendizaje-servicio (ApS) como medio generador de conocimiento y reflexión en los estudiantes de los grados de Educación Infantil y Educación Primaria

Memoria ID2019/045. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2019-2020

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment

Ehlers-Danlos Syndrome Type VIIC: A Mexican Case Report

Ehlers-Danlos syndrome (EDS) is a heterogeneous group of heritable connective tissue disorders whose primary clinicalfeatures include soft and extensible skin, articular hypermobility and tissue fragility. EDS type VIIC or ‘human dermatosparaxis’ is an autosomal recessive disease characterized by severe skin fragility and sagging redundant skin (major criteria) with a soft, doughy texture, easy bruising, premature rupture of fetal membranes and large hernias (minor criteria). Dermatosparaxis (meaning ‘tearing of skin’), which has been described in several non-human species, is a disorder of the connective tissue resulting from a deficiency of the enzyme that cleaves the registration peptide off the N-terminal end of collagen after it has been secreted from fibroblasts. We describe a Mexican case from consanguineous parents with all the phenotypical characteristics previously described, plus skeletal abnormalities

Posicionamiento de la Sociedad Española de Farmacia Clínica, Familiar y Comunitaria sobre telefarmacia: teleatención farmacéutica (TAF)

Las nuevas tecnologías de la información y comunicación (TIC) están desarrollándose desde hace bastantes años, pero la pandemia de COVID-19 ha acelerado la transformación digital de la sociedad. En el campo de la salud han surgido nuevas actividades y de esta forma términos como telemedicina, teleasistencia o teleconsulta empiezan a ser habituales. Indudablemente suponen un avance, pero tienen el riesgo de deshumanizar el contacto de sanitarios y pacientes. En el campo de la farmacia ha surgido la telefarmacia con unas innegables connotaciones logísticas y comerciales. Desde la Sociedad Española de Farmacia Clínica, Familiar y Comunitaria se prefiere utilizar el término teleatención farmacéutica (TAF), definiéndolo como la práctica farmacéutica asistencial a distancia que utiliza las TIC para complementar la atención farmacéutica presencial que precise el paciente. La TAF incluye la prestación a distancia de algunos servicios profesionales farmacéuticos asistenciales (SPFA). La TAF debe ayudar al farmacéutico comunitario a prestar algunos SPFA, mejorando así la practica farmacéutica clínica sin caer en la deshumanización que la aplicación indiscriminada de las TIC puede producir

Heterozygous and Homozygous Variants in SORL1 Gene in Alzheimer's Disease Patients: Clinical, Neuroimaging and Neuropathological Findings

In the last few years, the SORL1 gene has been strongly implicated in the development of Alzheimer’s disease (AD). We performed whole-exome sequencing on 37 patients with early-onset dementia or family history suggestive of autosomal dominant dementia. Data analysis was based on a custom panel that included 46 genes related to AD and dementia. SORL1 variants were present in a high proportion of patients with candidate variants (15%, 3/20). We expand the clinical manifestations associated with the SORL1 gene by reporting detailed clinical and neuroimaging findings of six unrelated patients with AD and SORL1 mutations. We also present for the first time a patient with the homozygous truncating variant c.364C>T (p.R122*) in SORL1, who also had severe cerebral amyloid angiopathy. Furthermore, we report neuropathological findings and immunochemistry assays from one patient with the splicing variant c.4519+5G>A in the SORL1 gene, in which AD was confirmed by neuropathological examination. Our results highlight the heterogeneity of clinical presentation and familial dementia background of SORL1-associated AD and suggest that SORL1 might be contributing to AD development as a risk factor gene rather than as a major autosomal dominant gene.This work was supported by the Instituto de Salud Carlos III (PI17/01067) and AGAUR from the Autonomous Catalan Government (2017SGR1134). Dr. Víctor Antonio Blanco-Palmero is supported by the Instituto de Salud Carlos III (ISCIII, Spanish Biomedical Research Institute) through a “Río Hortega” contract (CM18/0095). Dr. Sara Llamas-Velasco is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) through a “Juan Rodés” contract (JR 18/00046).S